SCHEMBL17970655

SCHEMBL17970655

Cc1n[nH]c2cc(-c3n[nH]c4ncnc(N)c34)ccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.51
PIK3CD O00329 3/20 0.51
PIK3CA P42336 3/20 0.51
PIK3CB P42338 3/20 0.51
PIK3CG P48736 3/20 0.51
PRKDC P78527 3/20 0.51
ABL1 P00519 2/20 0.51
EGFR P00533 2/20 0.51
HCK P08631 2/20 0.51
SRC P12931 2/20 0.51
MTOR P42345 2/20 0.51
EPHB4 P54760 2/20 0.51
PDPK1 O15530 11/20 0.43
SGK1 O00141 1/20 0.41
AURKA O14965 3/20 0.40
TGFBR1 P36897 3/20 0.40
ROCK1 Q13464 3/20 0.40
AURKB Q96GD4 3/20 0.40
JAK2 O60674 1/20 0.40
FGFR1 P11362 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21467105 0.90 JAK2 (0.46) KDRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL21467052 0.84 KDR (0.48) KDRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL17970622 0.82 KDR (0.44) KDRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL129811 0.80 PIK3CD (0.63) KDRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL13826604 0.79 LRRK2 (0.47) PDPK1JAK3
SCHEMBL22275989 0.79 MAP4K4 (0.49) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL19414427 0.78 PIK3CD (0.43) KDRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3782102 0.78 PIK3CD (0.57) KDRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL21467079 0.78 TGFBR1 (0.46) KDRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL30386858 0.76 PIK3CD (0.61) KDRPIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A KDR 823/4885PIK3CD 103/4885PIK3CA 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.